01—Abstract
Summary
Summary of the 8-K filed August 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) has filed an 8-K to disclose the transition of certain Walgreens volume servicing outside of its prime vendor agreement.
This transition, which began on July 1, 2026, was fully anticipated by the company and was factored into its previously communicated expectations for the U.S. Healthcare Solutions segment for the fourth quarter. Importantly, the prime vendor agreement itself, which represents the substantial majority of Cencora's business with Walgreens, remains unchanged.
In light of this disclosed information and its prior commentary, Cencora is reaffirming its adjusted diluted Earnings Per Share (EPS) guidance range of $17.75 to $17.95a for the fiscal year 2026. This reaffirms management's confidence in the company's ability to absorb the impact of the transitioning volume and meet its full-year financial targets.
02—Key points
Key Highlights
- Disclosure of certain Walgreens volume transitioning away from Cencora, effective July 1, 2026.
- The transitioned volume was separate from the primary prime vendor agreement with Walgreens.
- The prime vendor agreement, representing the majority of Cencora's business with Walgreens, remains unchanged.
- The company had previously contemplated this volume shift in its August 5, 2026, fourth-quarter commentary.
- Cencora is reaffirming its fiscal year 2026 adjusted diluted EPS guidance range of $17.75 to $17.95.
- The reaffirmation of guidance suggests management confidence in absorbing the impact of the volume shift.
03—Questions
Frequently Asked Questions
What specific Walgreens volume is transitioning away from Cencora?
The filing states that certain Walgreens volume that was being serviced by Cencora separate from the prime vendor agreement began moving outside the Company starting July 1, 2026.
Does this impact the main contract Cencora has with Walgreens?
No, the filing explicitly states that the prime vendor agreement, which constitutes the vast majority of Cencora's business with Walgreens, remains unchanged.
Did Cencora anticipate this change?
Yes, the company indicates that this transition was fully contemplated and factored into its August 5, 2026 commentary on fourth-quarter expectations for its U.S. Healthcare Solutions segment.
Has Cencora updated its full-year earnings guidance?
No, Cencora is reaffirming its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026.
04—Continue